NeoGenomics (NeoGenomics) Net Margin %

: -9.21% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. NeoGenomics's Net Income for the three months ended in Dec. 2023 was $-14.3 Mil. NeoGenomics's Revenue for the three months ended in Dec. 2023 was $155.6 Mil. Therefore, NeoGenomics's net margin for the quarter that ended in Dec. 2023 was -9.21%.

The historical rank and industry rank for NeoGenomics's Net Margin % or its related term are showing as below:

NEO' s Net Margin % Range Over the Past 10 Years
Min: -28.3 Med: -0.94 Max: 1.96
Current: -14.87

NEO's Net Margin % is ranked worse than
53.1% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.145 vs NEO: -14.87

NeoGenomics Net Margin % Historical Data

The historical data trend for NeoGenomics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

1.96

0.94

-1.72

-28.30

-14.87

NeoGenomics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-16.36	-22.44	-16.56	-12.19	-9.21

Competitive Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoGenomics Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Net Margin % distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Net Margin % falls into.

NeoGenomics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NeoGenomics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-87.968	/	591.643
	=	-14.87 %

NeoGenomics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-14.326	/	155.552
	=	-9.21 %

NeoGenomics (NAS:NEO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

NeoGenomics Net Margin % Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics (NeoGenomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Executives

Alicia C Olivo	officer: General Counsel	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan	officer: Chief Accounting Officer	HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman	officer: Chief Financial Officer	103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris	officer: President, Enterprise Ops	4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith	officer: Chief Executive Officer	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni	officer: President of Lab Operations	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri	officer: President and CCO, Inivata	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello	officer: VP, Investor Relations	12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie	officer: Principal Accounting Officer	12780 WESTLINKS DRIVE, FORT MYERS FL 33913